Literature DB >> 7769128

Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis.

T Kasama1, R M Strieter, N W Lukacs, P M Lincoln, M D Burdick, S L Kunkel.   

Abstract

In the enclosed study we have examined the expression and contribution of specific chemokines, macrophage inflammatory protein 1 alpha (MIP-1 alpha) and macrophage inflammatory protein 2 (MIP-2), and interleukin 10 (IL-10) during the evolution of type II collagen-induced arthritis (CIA). Detectable levels of chemotactic cytokine protein for MIP-1 alpha and MIP-2 were first observed between days 32 and 36, after initial type II collagen challenge, while increases in IL-10 were found between days 36 and 44. CIA mice passively immunized with antibodies directed against either MIP-1 alpha or MIP-2 demonstrated a delay in the onset of arthritis and a reduction of the severity of arthritis. On the contrary, CIA mice receiving neutralizing anti-IL-10 antibodies demonstrated an acceleration of the onset and an increase in the severity of arthritis. Interestingly, anti-IL-10 treatment increased the expression of MIP-1 alpha and MIP-2, as well as increased myeloperoxidase (MPO) activity and leukocyte infiltration in the inflamed joints. These data suggest that MIP-1 alpha and MIP-2 play a crucial role in the initiation and maintenance, while IL-10 appears to play a regulatory role during the development of experimental arthritis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7769128      PMCID: PMC295974          DOI: 10.1172/JCI117993

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  56 in total

1.  Interleukin-1 enhances the development of type II collagen-induced arthritis only in susceptible and not in resistant mice.

Authors:  J T Hom; H Cole; T Estridge; V L Gliszczynski
Journal:  Clin Immunol Immunopathol       Date:  1992-01

Review 2.  Interleukin-8 and related chemotactic cytokines--CXC and CC chemokines.

Authors:  M Baggiolini; B Dewald; B Moser
Journal:  Adv Immunol       Date:  1994       Impact factor: 3.543

3.  Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor.

Authors:  P F Piguet; G E Grau; C Vesin; H Loetscher; R Gentz; W Lesslauer
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

4.  Interleukin 1 mediated acceleration of type II collagen-induced arthritis: effects of anti-inflammatory or anti-arthritic drugs.

Authors:  J T Hom; V L Gliszczynski; H W Cole; A M Bendele
Journal:  Agents Actions       Date:  1991-07

5.  Regulation of neutrophil-derived chemokine expression by IL-10.

Authors:  T Kasama; R M Strieter; N W Lukacs; M D Burdick; S L Kunkel
Journal:  J Immunol       Date:  1994-04-01       Impact factor: 5.422

6.  Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis.

Authors:  A E Koch; S L Kunkel; L A Harlow; D D Mazarakis; G K Haines; M D Burdick; R M Pope; R M Strieter
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

7.  Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice.

Authors:  P H Wooley; J Dutcher; M B Widmer; S Gillis
Journal:  J Immunol       Date:  1993-12-01       Impact factor: 5.422

8.  Interleukin-10 production during septicaemia.

Authors:  A Marchant; J Devière; B Byl; D De Groote; J L Vincent; M Goldman
Journal:  Lancet       Date:  1994-03-19       Impact factor: 79.321

9.  Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide.

Authors:  M A Cassatella; L Meda; S Bonora; M Ceska; G Constantin
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

10.  Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice.

Authors:  H Ishida; T Muchamuel; S Sakaguchi; S Andrade; S Menon; M Howard
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

View more
  75 in total

1.  Interleukin 10 treatment for rheumatoid arthritis.

Authors:  E W St Clair
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  New therapies in development for autoimmune diseases: their rationale for combination treatment.

Authors:  V Strand
Journal:  Springer Semin Immunopathol       Date:  2001

3.  Interleukin-10 ameliorates the outcome of Staphylococcus aureus arthritis by promoting bacterial clearance.

Authors:  I Gjertsson; O H Hultgren; A Tarkowski
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

4.  Macrophage inflammatory protein 1 alpha expression by synovial fluid neutrophils in rheumatoid arthritis.

Authors:  Y Hatano; T Kasama; H Iwabuchi; R Hanaoka; H T Takeuchi; L Jing; Y Mori; K Kobayashi; M Negishi; H Ide; M Adachi
Journal:  Ann Rheum Dis       Date:  1999-05       Impact factor: 19.103

5.  Production of interleukin (IL)-5 and IL-10 accompanies T helper cell type 1 (Th1) cytokine responses to a major thyroid self-antigen, thyroglobulin, in health and autoimmune thyroid disease.

Authors:  C H Nielsen; L Hegedüs; K Rieneck; A C Moeller; R G Q Leslie; K Bendtzen
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

6.  Adrenomedullin protects from experimental arthritis by down-regulating inflammation and Th1 response and inducing regulatory T cells.

Authors:  Elena Gonzalez-Rey; Alejo Chorny; Francisco O'Valle; Mario Delgado
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

7.  Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy.

Authors:  Tetsuya Amano; Satoshi Yamasaki; Naoko Yagishita; Kaneyuki Tsuchimochi; Hiroshi Shin; Ko-ichi Kawahara; Satoko Aratani; Hidetoshi Fujita; Lei Zhang; Rie Ikeda; Ryoji Fujii; Naoki Miura; Setsuro Komiya; Kusuki Nishioka; Ikuro Maruyama; Akiyoshi Fukamizu; Toshihiro Nakajima
Journal:  Genes Dev       Date:  2003-09-15       Impact factor: 11.361

Review 8.  Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy.

Authors:  Ankit Saxena; Sam Khosraviani; Sanjeev Noel; Divya Mohan; Thomas Donner; Abdel Rahim A Hamad
Journal:  Cytokine       Date:  2014-12-04       Impact factor: 3.861

Review 9.  The role of chemokines in leucocyte-stromal interactions in rheumatoid arthritis.

Authors:  Andrew Filer; Karim Raza; Mike Salmon; Christopher D Buckley
Journal:  Front Biosci       Date:  2008-01-01

10.  Treatment of mice with the neutrophil-depleting antibody RB6-8C5 results in early development of experimental lyme arthritis via the recruitment of Gr-1- polymorphonuclear leukocyte-like cells.

Authors:  Charles R Brown; Victoria A Blaho; Christie M Loiacono
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.